About Jonathan E. Dowell
Board Certified in Medical Oncology
Pleural and Lung Cancer
Excellence in Research
Part of excelling as a physician includes taking an active role in the care of patients. Dowell is a prime example of this – specifically showing interest in cancer patients. He conducts clinical trials for cancer from unknown primary sites as well as trials for patients with lung, neck and head malignancies.
In two studies, Dowell analyzed aspects of cancer treatment – going beyond simply looking at the physical results of treatment – by examining the behavior of patients and those employed in the medical field. Dowell, along with Sachin Shah and Shane Greene, published an evaluation of 423 chemotherapy patients undergoing follow-up care. Their study showed the extensive effort necessary for thorough outpatient care, recognizing the need for correct prescription adjustments and adequate pain management.
Trends of People in Clinical Trials
Dowell and his colleagues studied the consent trends of cancer patients in clinical trials. They presented their results before the 2010 American Society of Clinical Oncology annual meeting. They found that a patient’s consent to participate in research studies was influenced by whether or not the patient had been in trials before, the timing of the trial invitation and by the gender of the consenter.
Future cancer studies may be improved by Dowell’s analysis of patient consent, allowing larger population samples to be collected and better patient responses to be gleaned.
In another journal, Dowell provided an up to date summary of clinical trials examining whether or not manipulating angiogenesis (the growth of new blood vessels) can help with tumor regression for malignant mesothelioma.
In addition to pursuing his own clinical interests, Dowell provides services for the University of Texas Southwestern Medical Center.
UT Southwestern MED magazine gives the story of a woman, Nancy, who was a patient under the care of Dowell and other doctors. Dowell found a cancerous lymph node in the Nancy’s chest and worked with other doctors to provide chemotherapy and radiation. As of 2011, Nancy was alive and well, seven years after her treatment.
The significance of Nancy’s survival after treatment was noted by Dowell. He said, “What is miraculous is that nothing has ever come back. It didn’t spread to other places [and . . . ] some of the reason is the team here at UT Southwestern treated her cancer very aggressively, because there was at least a chance we would cure this.”
Dowell is also involved in a joint project combining the efforts of The University of Texas Southwestern Medical Center and The University of Texas M. D. Anderson Cancer Center. The project aims to improve treatment strategies for lung cancer.
Talk to a Doctor About Your Diagnosis
We can help you or a loved one get in contact with Dr. Dowell and find the treatment that's best for you.Get Started Today
Active in Research
Dowell is a co-investigator on one of five programs, which seeks to manipulate telomerase activity to prevent tumor growth.
Dowell stays active in the medical research community and participated in the 13th World Conference on Lung Cancer in 2009, where mesothelioma papers where shared. Dowell focused on therapeutic intervention in cancer treatment, specifically chemotherapy for late-stage patients. Leaders in the field, such as Dr. David Sugarbaker, also spoke at this conference.
Dowell gave a presentation at the 2012 Lung Cancer & Other Thoracic Malignancies: Advances in the Management and Diagnosis Symposium, offering insights on mesothelioma diagnosis, staging and treatments results.
The interest and expertise in internal medicine offered by Jonathan Dowell provides hope in understanding the complexities of mesothelioma.
Disclaimer: Dr. Jonathan E. Dowell has no professional affiliation with Asbestos.com.
8 Cited Article Sources
- The University of Texas Southwestern Medical Center. (2012). Jonathan Dowell, M.D. Retrieved from: http://www.utsouthwestern.edu/fis/faculty/11902/jonathan-dowell.html
- American Society of Clinical Oncology. (2012). A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM). Retrieved from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32851
- The University of Texas Southwestern Medical Center. (2012). Lung Cancer & Other Thoracic Malignancies: Advances in the Management and Diagnosis. Retrieved from: http://utsouthwestern.edu/about-us/administrative-offices/continuing-medical-education/symposia/lung-cancer/agenda.html
- National Cancer Institute. (2012 September 17). University of Texas Southwestern Medical Center SPORE in Lung Cancer. Retrieved from: http://trp.cancer.gov/spores/abstracts/utsouthwestern_lung.htm
- Shah, S., Dowell, J. & Greene, S. (2006 September ). Evaluation of clinical pharmacy services in hematology/oncology outpatient setting. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/16882869
- Dowell, J. & Kindler, H. (2005 Dec.). Antiangiogenic therapies for mesothelioma. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/16325128
- American Society of Clinical Oncology. (2012). Consenting factors in clinical research: observations from a cancer center tissue repository. Retrieved from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=31191
- International Association For The Study of Lung Cancer. (2009). 13th World Conference on Lung Cancer. Retrieved from: https://www.iaslc.org/events/13th-world-conference-lung-cancer
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified April 10, 2019